PHE's Huber Leads New Study on Social, Economic Impacts of 2014 Ebola Crisis
Led by Caroline Huber, Associate Director of Policy and Economics, a surprising new study was recently published in The Journal of Infectious Diseases, estimating the overlooked social, economic and health impacts of the 2013-2016 West Africa Ebola crisis.
Along with her colleagues, Dr. Huber estimated that overall costs of the Ebola outbreak totaled more than $53 billion, exceeding previous estimates by more than $20 billion. Factoring in deaths from non-Ebola causes during this period, the study provides valuable new data on the overall impact of the crisis and identified specific costs missed by other accountings to determine the overall global costs of the unprecedented outbreak.
The study’s release has generated a significant amount of media interest, with coverage appearing in numerous outlets including Reuters and the BBC, who interviewed Dr. Huber as part of their Newsday radio program.
To read more about the study and the findings of Dr. Huber and her research team, read the complete article: The Economic and Social Burden of the 2014 Ebola Outbreak in West Africa.
In addition, a concise summary of the study can be found on the Science Speaks blog.
By: Jason Shafrin, PhD Sr. Director, Policy and Economics and Jacki Chou, MPP, MPL Senior Director, Policy and Economics The recent announcement that CVS Caremark will use value-based metrics to inform formulary design at first appears a step in the right direction. However, using value measurements from a single nongovernmental organization—the Institute for Clinical and Economic Review (ICER)—based on a limited picture of treatment value may be problematic. Using this single assessment of value in an effort solely to exclude drugs from a major insurance formulary is even more worrisome and fails to recognize the heterogeneity in patient clinical needs and preferences.